AstraZeneca, the FTSE 100 pharmaceutical giant, has reaffirmed its full-year forecasts despite posting mixed first-quarter results and grappling with potential headwinds in major markets. The company reported a 10 per
AstraZeneca, the FTSE 100 pharmaceutical giant, has reaffirmed its full-year forecasts despite posting mixed first-quarter results and grappling with potential headwinds in major markets. The company reported a 10 per






